AU1652601A - New combination comprising a beta2-adrenoreceptor agonist and a leukotriene receptor antagonist - Google Patents

New combination comprising a beta2-adrenoreceptor agonist and a leukotriene receptor antagonist

Info

Publication number
AU1652601A
AU1652601A AU16526/01A AU1652601A AU1652601A AU 1652601 A AU1652601 A AU 1652601A AU 16526/01 A AU16526/01 A AU 16526/01A AU 1652601 A AU1652601 A AU 1652601A AU 1652601 A AU1652601 A AU 1652601A
Authority
AU
Australia
Prior art keywords
beta2
receptor antagonist
new combination
leukotriene receptor
adrenoreceptor agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU16526/01A
Other languages
English (en)
Inventor
Jan Trofast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU1652601A publication Critical patent/AU1652601A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU16526/01A 1999-11-03 2000-10-27 New combination comprising a beta2-adrenoreceptor agonist and a leukotriene receptor antagonist Abandoned AU1652601A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9903995 1999-11-03
SE9903995A SE9903995D0 (sv) 1999-11-03 1999-11-03 New combination
PCT/SE2000/002116 WO2001032166A1 (en) 1999-11-03 2000-10-27 NEW COMBINATION COMPRISING A β2-ADRENORECEPTOR AGONIST AND A LEUKOTRIENE RECEPTOR ANTAGONIST

Publications (1)

Publication Number Publication Date
AU1652601A true AU1652601A (en) 2001-05-14

Family

ID=20417605

Family Applications (2)

Application Number Title Priority Date Filing Date
AU16526/01A Abandoned AU1652601A (en) 1999-11-03 2000-10-27 New combination comprising a beta2-adrenoreceptor agonist and a leukotriene receptor antagonist
AU13214/01A Abandoned AU1321401A (en) 1999-11-03 2000-10-27 New combination comprising a beta 2 (beta)2 adreno receptor agonist and a leukotriene receptor antagonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU13214/01A Abandoned AU1321401A (en) 1999-11-03 2000-10-27 New combination comprising a beta 2 (beta)2 adreno receptor agonist and a leukotriene receptor antagonist

Country Status (13)

Country Link
EP (1) EP1242065A1 (ja)
JP (1) JP2003513037A (ja)
KR (1) KR20020050254A (ja)
CN (1) CN1387431A (ja)
AU (2) AU1652601A (ja)
BR (1) BR0015172A (ja)
CA (1) CA2388657A1 (ja)
IL (1) IL149365A0 (ja)
MX (1) MXPA02004334A (ja)
NO (1) NO20022103D0 (ja)
SE (1) SE9903995D0 (ja)
WO (2) WO2001032166A1 (ja)
ZA (1) ZA200203178B (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
PE20050130A1 (es) * 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
GB0312148D0 (en) * 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
WO2005097095A1 (en) * 2004-04-05 2005-10-20 Sepracor Inc. (r,r)-formoterol in combination with other pharmacological agents
ES2245612B1 (es) * 2004-06-29 2007-08-16 Universidad De Barcelona Nuevo uso terapeutico del formoterol.
JP4991693B2 (ja) * 2005-03-16 2012-08-01 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤
CN103562185A (zh) 2011-06-06 2014-02-05 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物
KR102192739B1 (ko) * 2012-12-05 2020-12-18 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체
JP5846185B2 (ja) 2013-11-21 2016-01-20 大日本印刷株式会社 貫通電極基板及び貫通電極基板を用いた半導体装置
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604752D0 (sv) * 1996-12-20 1996-12-20 Astra Ab Formulation and use
AU726210B2 (en) * 1997-03-13 2000-11-02 Merck Frosst Canada Ltd. Quinoline leukotriene antagonists
SE9704644D0 (sv) * 1997-12-12 1997-12-12 Astra Ab New use

Also Published As

Publication number Publication date
BR0015172A (pt) 2002-06-18
NO20022103L (no) 2002-05-02
NO20022103D0 (no) 2002-05-02
MXPA02004334A (es) 2002-11-07
CA2388657A1 (en) 2001-05-10
IL149365A0 (en) 2002-11-10
WO2001032166A1 (en) 2001-05-10
WO2001032163A1 (en) 2001-05-10
KR20020050254A (ko) 2002-06-26
AU1321401A (en) 2001-05-14
CN1387431A (zh) 2002-12-25
SE9903995D0 (sv) 1999-11-03
ZA200203178B (en) 2003-07-22
JP2003513037A (ja) 2003-04-08
EP1242065A1 (en) 2002-09-25

Similar Documents

Publication Publication Date Title
AU4336899A (en) Novel leukotriene receptor antagonists and their uses
AU3080499A (en) Analgesic combination comprising nmda receptor antagonists and narcotic analgesics
AU7079498A (en) Neuropeptide y receptor antagonist
AU4698299A (en) 5-HT7 receptor antagonists
AU8689798A (en) Integrin receptor antagonists
IL137990A0 (en) A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
EP1229910A4 (en) integrin
EP1194151A4 (en) ANTAGONISTS OF THE INTEGRIN RECEPTORS
AU775774C (en) Peroxisome proliferator-activated receptor agonist
AU1652601A (en) New combination comprising a beta2-adrenoreceptor agonist and a leukotriene receptor antagonist
AUPP380498A0 (en) Egf receptor agonists and antagonists
AU2371400A (en) Vitronectin receptor antagonist pharmaceuticals
IL138576A0 (en) A novel interleukin-1 receptor antagonist and uses thereof
AU2001290772A1 (en) Alpha v integrin receptor antagonists
AU2441801A (en) Urotensin-ii receptor antagonists
AU2001286409A1 (en) N-methyl-d-aspartate receptor antagonists
AU6990000A (en) Novel integrin receptor antagonists
AU5861900A (en) Receptor agonists and antagonists
AU2001225663A1 (en) A composition comprising a combination of receptor agonists and antagonists
AU6230698A (en) Dopamine d4 receptor antagonist
GB9820014D0 (en) Receptor antagonists and uses thereof
IL146146A0 (en) Integrin receptor antagonists
AU1100300A (en) Piperidyloxadiazoles as dopamine receptor antagonists
AU2574801A (en) Selective iGLUR5 receptor antagonists
HU0002979D0 (en) Estrogen agonists and antagonists for multiple indications

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase